方法：分析2014-06/12我院确诊为视网膜静脉阻塞伴有黄斑水肿39例39眼患者资料，患眼给予玻璃体腔注射0.05mL ranibizumab，于注射后2d，2、4wk复查最佳矫正视力(BCVA)、黄斑中心厚度(CMT)、黄斑区平均厚度(CAT)。

结果：治疗前BCVA(LogMAR值)为0.82±0.45，CMT为 541±136μm，CAT为382±107μm。玻璃体腔内首次注射ranibizumab后平均BCVA在治疗后2d，2、4wk后分别为0.56±0.35、0.48±0.39、0.51±0.44，与治疗前比较明显提高(P<0.01)。平均CMT在治疗后2d，2、4wk后分别为372±86、281±74、286±97μm(P<0.01)。平均CAT在治疗后2d，2、4wk后分别为331±46、312±54、319±68μm(P<0.01)，与治疗前比较得到了明显降低。

结论：玻璃体腔首次注射ranibizumab 能够改善视网膜静脉阻塞继发黄斑水肿，提高视力，短期疗效明确，但远期疗效仍有待观察。

METHODS: Thirty-nine eyes of 39 patients with macular edema due to RVO were treated in our hospital during June 2014 to December 2014. Patients received intravitreal injection of 0.05mL ranibizumab. Best corrected visual acuity(BCVA), central macular thickness(CMT)and cube average thickness(CAT)were analyzed at 2d, 2, and 4wk after injection, respectively.

RESULTS: The baseline BCVA(LogMAR), CMT and CAT were 0.82±0. 45, 541±136μm and 382±107μm before treatment. After first ranibizumab intravitreal injection, mean BVCA significantly improved at 2d(0. 56±0.35,P<0.01), 2wk(0.48±0.39,P<0.01), 4wk(0.51±0.44, P<0.01), compared to baseline BCVA. Mean CMT also decreased at 2d(372±86μm, P<0.01), 2wk(281±74μm, P<0.01), 4wk(286±97μm, P<0.01), mean CAT also decreased at 2d(331±46μm, P<0.01), 2wk(312±54μm, P<0.01), 4wk(319±68μm, P<0.01), compared to baseline BCVA.

CONCLUSION: First intravitreal injection of ranibizumab can improve macular edema caused by RVO in short-term, but long-term effects is needed further observed.